UCL Technology Fund has participated in a $145m round that will allow Apollo Therapeutics to advance assets into the clinic and open a US office.

Apollo Therapeutics, a UK-based biopharmaceutical joint venture involving University of Cambridge, Imperial College London and University College London (UCL), closed a $145m round today backed by the latter’s UCL Technology Fund. Patient Square Capital led the transaction, which also attracted Rock Springs Capital and Reimagined Ventures. Apollo Therapeutics was established in late 2015 by tech…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.